Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAuNS@PEG-bio is an experimental **biotin-decorated hollow gold nanoshell nanoparticle** developed as a theranostic agent for breast cancer. It is produced by generating hollow gold nanoshells and further surface-functionalizing them with biotin-PEG-SH to improve tumor-cell targeting. In the cited preclinical work, the construct is intended to support **NIR-II photothermal therapy**, **CT and infrared thermal imaging guidance**, and **radiosensitization**; its therapeutic concept relies on strong X-ray absorption by gold and photothermal heating that can improve tumor oxygenation, thereby enhancing radiotherapy and promoting immunogenic cell death in tumors. The available evidence appears to be preclinical and publication-based rather than from a named commercial development program.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HAuNS@PEG-bio.